Aliskiren

Active ingredient description

Aliskiren is an orally active, non-peptide, potent and selective direct inhibitor of human renin. By inhibiting the enzyme renin, aliskiren inhibits the RAAS at the point of activation, blocking the conversion of angiotensinogen to angiotensin I and decreasing levels of angiotensin I and angiotensin II.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
C09XA02
Aliskiren
C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09X Other agents acting on the renin-angiotensin system → C09XA Renin-inhibitors
Discover more medicines within C09XA02

Medicines

Aliskiren is the active ingredient of these drugs:

Drug
Countries
ALISKIREN

United States

RASILEZ

Austria Canada Cyprus Hong Kong Ireland

RIPRAZO

Ireland

TEKTURNA

United States

Aliskiren is also found within below combination drugs:

RASILAMLO , RASILEZ HCT , TEKTURNA HCT

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
RASILEZ Film-coated tablet
Summary of product characteristics (SPC)

Structural formula

Graphic representation of the active ingredient's molecular structure

Unique ingredient identifier (UNII)

502FWN4Q32 - ALISKIREN

CAS registry number

173334-57-1 - aliskiren

SNOMED-CT

426725002 - Aliskiren (substance)

Next: Usage